|
|
Title Abreviation: Eur J Clin Pharmacology
Date of Pub: 1995
Author: PiĶerard-Franchimont C; Goffin V; Visser JN; Jacoby H;
PiĶerard GE;
Issue/Part/Supplement: 1-2
Volume Issue: 49
Pagination: 57-60
MESH Headings: Acetic Acids; Acne Vulgaris; Administration, Topical;
Adult; Antibiotics, Macrolide; Double-Blind Method; Drug Therapy, Combination;
Erythromycin; Human; Male; Sebum; -PG-;
Journal Title Code: EN4
Publication Type: CLINICAL TRIAL
Date of Entry: 960923N
Entry Month: 9611
Country: GERMANY
Index Priority: 2
Language: Eng
Unique Identifier: 96287397
Unique Identifier: 96287397
ISSN: 0031-6970
Abstract:
In a double-blind randomised study, 14 volunteers applied
4% erythromycin plus 1.2% zinc (Zineryt lotion) and 4% erythromycin lotions, each
on half of the forehead twice daily for 3 months. The sebum output was evaluated at 3-week
intervals using the photometric and the lipid-sensitive film methods. Evaluations of
casual level (CL) and sebum excretion rate (SER) were made with a Sebumeter, and total
area of lipid spots (TAS) was measured on Sebutapes. Compared to baseline values, the
formulation of the erythromycin-zinc complex induced significant reductions in SER
after 6 and 9 weeks, and in CL and TAS at 3, 6, 9 and 12 weeks. The mean reduction in TAS
was over 20% for four successive 1-h samplings on completion of the study. Significant
reductions in CL, SER and TAS were observed for the erythromycin-zinc formulation
compared to the control lotion at 6 and 9 weeks, and also at 3 weeks for SER and TAS, and
at 12 weeks for CL and TAS. This study indicates that sebum output is significantly
reduced by the erythromycin-zinc complex. This reduction is theoretically
beneficial for the acneic patient.
Abstract By: Author
Address: Department of Dermatopathology, University of Liege,
Belgium.
Information, statements and products on this website have not been evaluated by the FDA and are not intended to diagnose, mitigate, treat, cure, or prevent any disease or health condition.
All Rights Reserved
|
